Fluidigm, which makes high-throughput sequencing devices for genetic labs, announced terms for its IPO on Friday. The South San Francisco, CA-based company plans to raise $75 million by offering 5.2 million shares at a price range of $13.50-$15.50. At the mid-point of the proposed range, Fluidigm will command a market value of $270 million. Fluidigm, which was founded in 1999 and booked $31 million in sales for the 12 months ended September 30, 2010, plans to list on the NASDAQ under the symbol FLDM. Deutsche Bank Securities and Piper Jaffray are the lead underwriters on the deal, which is expected to price during the week of February 7. Fluidigm previously attempted to go public in September 2008 before shelving the deal due to market conditions.
